Revox Sterilization Solutions

Revox Sterilization Solutions
Share

As medtech advances, device makers need to consider sterilization methods that won’t compromise electronics, drugs or biologics. The medical device industry has undergone an impressive transformation over the last several years, resulting in new and innovative devices and solutions. As companies continue to innovate, they are finding that commonly...

Infographic: Top 5 Reasons Why Ethylene Oxide (EO) is a Hazardous Sterilization Method.
To read more about other challenges of EO check out the article: Overcoming the Constraints of Legacy Sterilization Methods

On-site placement and operation of a vaporized peractic acid (VPA) sterilization unit is safe, simple, and efficient. Available large-capacity units can eliminate inefficiencies associated with off-site processing, such as long turnaround times, external quality processes, and the need to maintain large inventories. In-production-line -- or...

Revox Sterilization Solutions

 •  November 30, 2017

As medtech advances, device makers need to consider sterilization methods that won’t compromise electronics, drugs or biologics. The medical device industry has undergone an impressive transformation over the last several years, resulting in new and innovative devices and solutions. As companies continue to innovate, they are finding that commonly...

Revox Sterilization Solutions

 •  October 24, 2017

The medical device industry is increasingly relying upon the use of bioabsorbable implants, and that trend will continue to grow. In fact, the bioabsorbable stent market alone is expected to reach $2.4B by 2021, up from $400M in 2016, according to a 2016 MarketsandMarkets report. Traditional sterilization methods, however, have typically posed...

Revox Sterilization Solutions

 •  March 23, 2017

Matt Conlon, V.P. and General Manager of REVOX® Sterilization Solutions, discusses the latest advancements and opportunities in the medical technology and sterilization industries.
What is the biggest trend you have seen in the past year in the medical device market? MATT CONLON: There is an obvious trend toward biologics and combination devices....